High-sensitivity Opportunity Target biopharma and translational research organizations seeking ultra-sensitive multiplex protein profiling with attomolar detection and large dynamic range to enable early biomarker discovery and mechanistic biology studies.

Pancreatic Cancer Focus Leverage the PanDx assay read-out for early-stage cancer detection to engage oncology-focused researchers and clinical laboratories pursuing biomarker panels for early diagnosis and patient stratification.

Proven Differentiation Highlight the MPAD platform’s unique background lowering, antibody-pair architecture, and NGS read-out as a defensible differentiator to win deals against conventional multiplex proteomics providers.

Small Team Nimbleness Position ActivSignal as a specialized, agile partner for early-stage collaborations and pilot projects with academic labs and biotech startups that prefer fast iteration and customized assay development.

Strategic Partnerships Explore grant-funded collaborations and university partnerships, given prior Stage 1 award recognition and modest revenue scale, to expand go-to-market channels, evidence generation, and customer footprint in biotech hubs.